IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
AU1608397A
(en)
|
1996-02-02 |
1997-08-22 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2001518067A
(ja)
*
|
1996-04-03 |
2001-10-09 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシルプロテイントランスフェラーゼの阻害剤
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
JP2000507581A
(ja)
*
|
1996-04-03 |
2000-06-20 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル―タンパク質転移酵素の阻害剤
|
CA2250143A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Jeffrey Bergman |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
JP2000504023A
(ja)
*
|
1996-04-03 |
2000-04-04 |
メルク エンド カンパニー インコーポレーテッド |
癌治療方法
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
EP0891335A4
(en)
*
|
1996-04-03 |
2001-08-16 |
Merck & Co Inc |
FARNESYL-PROTEIN TRANSFERASE INHIBITORS
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
AU715202B2
(en)
*
|
1996-04-03 |
2000-01-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
WO1997036592A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
TR199900303T2
(xx)
*
|
1996-08-14 |
1999-06-21 |
Zeneca Limited |
�kame edilmi� pirimidin t�revleri ve bunlar�n farmas�tik kullan�m�.
|
UA56197C2
(uk)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
EP1003374A4
(en)
*
|
1996-12-30 |
2000-05-31 |
Merck & Co Inc |
INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
|
US6440972B1
(en)
|
1997-02-13 |
2002-08-27 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
ATE242774T1
(de)
|
1997-02-13 |
2003-06-15 |
Astrazeneca Ab |
Heterozyklische verbindungen die als oxido- squalen-zyklase-inhibitoren anwendung finden
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
JP2001514191A
(ja)
*
|
1997-08-27 |
2001-09-11 |
メルク エンド カムパニー インコーポレーテッド |
癌の治療方法
|
AU2286099A
(en)
*
|
1998-02-13 |
1999-08-30 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
FR2774985A1
(fr)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
Nouveaux derives de naphthyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
|
WO2000001691A1
(en)
*
|
1998-07-01 |
2000-01-13 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
CA2362778A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
AU3390000A
(en)
*
|
1999-03-03 |
2000-09-21 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2363169A1
(en)
*
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP1165082A4
(en)
*
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
PRENYLE PROTEIN TRANSFERASE INHIBITORS
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819512B1
(fr)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
FR2819510B1
(fr)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent
|
FR2819509B1
(fr)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
Nouveaux composes cycloheptene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
EP1940786B1
(en)
|
2005-09-16 |
2010-08-18 |
Arrow Therapeutics Limited |
Biphenyl derivatives and their use in treating hepatitis c
|
LT2474545T
(lt)
|
2005-12-13 |
2017-02-27 |
Incyte Holdings Corporation |
Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2946778A1
(en)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US8436035B2
(en)
*
|
2006-12-18 |
2013-05-07 |
Novartis Ag |
Organic compounds
|
EP2109608B1
(en)
|
2007-01-10 |
2011-03-23 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
EA019951B1
(ru)
|
2007-03-01 |
2014-07-30 |
Новартис Аг |
Ингибиторы киназы pim и способы их применения
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
CA2689663C
(en)
|
2007-06-13 |
2016-08-09 |
Incyte Corporation |
Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
MX337100B
(es)
|
2007-10-05 |
2016-02-11 |
Acucela Inc |
Compuestos alcoxi para el tratamiento de enfermedades.
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
JP6067226B2
(ja)
|
2009-03-13 |
2017-01-25 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
細胞増殖関連疾患のための方法および組成物
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
AU2010234526B2
(en)
|
2009-04-06 |
2016-07-21 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use
|
BRPI1012159B1
(pt)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
DK2432472T3
(da)
|
2009-05-22 |
2019-11-18 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
|
WO2010144909A1
(en)
|
2009-06-12 |
2010-12-16 |
Novartis Ag |
Fused heterocyclic compounds and their uses
|
NZ597379A
(en)
|
2009-06-29 |
2014-04-30 |
Agios Pharmaceuticals Inc |
Therapeutic compounds and compositions
|
WO2011003103A2
(en)
|
2009-07-02 |
2011-01-06 |
Acucela, Inc. |
Pharmacology of visual cycle modulators
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CN104945382B
(zh)
|
2009-10-14 |
2020-02-07 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
EP2491145B1
(en)
|
2009-10-21 |
2016-03-09 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
EP2519517B1
(en)
|
2009-12-29 |
2015-03-25 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
KR20220015492A
(ko)
|
2010-03-10 |
2022-02-08 |
인사이트 홀딩스 코포레이션 |
Jak1 저해제로서의 피페리딘4일 아제티딘 유도체
|
EA201290919A1
(ru)
|
2010-03-16 |
2013-03-29 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Индазольные соединения и их применение
|
PL2574168T3
(pl)
|
2010-05-21 |
2016-10-31 |
|
Preparaty inhibitora kinazy janusowej do stosowania miejscowego
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
CN108676800B
(zh)
|
2010-08-17 |
2022-11-11 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
ES2663009T3
(es)
|
2010-10-29 |
2018-04-10 |
Sirna Therapeutics, Inc. |
Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
WO2012083246A1
(en)
|
2010-12-17 |
2012-06-21 |
Agios Pharmaceuticals, Inc. |
Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
CA2822432C
(en)
|
2010-12-21 |
2019-09-24 |
Agios Pharmaceuticals, Inc. |
Bicyclic pkm2 activators
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
CN108451955B
(zh)
|
2011-05-03 |
2022-02-01 |
安吉奥斯医药品有限公司 |
用于治疗的丙酮酸激酶活化剂
|
EP2704720B1
(en)
|
2011-05-03 |
2019-08-07 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase r activators for use in therapy
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
EP2721028B1
(en)
|
2011-06-20 |
2015-11-04 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
JP6106685B2
(ja)
|
2011-11-17 |
2017-04-05 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
C−jun−n−末端キナーゼ(jnk)の阻害剤
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
JP6399660B2
(ja)
*
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
PE20200175A1
(es)
|
2012-11-15 |
2020-01-24 |
Incyte Holdings Corp |
Formas de dosificacion de ruxolitinib de liberacion sostenida
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
AU2013361694B2
(en)
|
2012-12-20 |
2017-10-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as HDM2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
UA120162C2
(uk)
|
2013-03-06 |
2019-10-25 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки при отриманні інгібітора jak
|
RS59411B1
(sr)
|
2013-03-13 |
2019-11-29 |
Forma Therapeutics Inc |
Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodna jedinjenja kao inhibitori sintaze masnih kiselina (fasn) za lečenje kancera
|
JP6529492B2
(ja)
|
2013-07-11 |
2019-06-12 |
アジオス ファーマシューティカルズ, インコーポレイテッド |
癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
CA3155500A1
(en)
|
2013-08-07 |
2015-02-12 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
KR20240010105A
(ko)
|
2014-03-14 |
2024-01-23 |
아지오스 파마슈티컬스 아이엔씨. |
치료적으로 활성인 화합물의 약제학적 조성물
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
US10017477B2
(en)
|
2014-04-23 |
2018-07-10 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
JP6499306B2
(ja)
|
2014-10-24 |
2019-04-10 |
ランドス バイオファーマ インコーポレイテッド |
ランチオニンシンテターゼc様2系治療薬
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US10550121B2
(en)
|
2015-03-27 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
PL3307271T3
(pl)
|
2015-06-11 |
2024-02-05 |
Agios Pharmaceuticals, Inc. |
Sposoby stosowania aktywatorów kinazy pirogronianowej
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016338557B2
(en)
|
2015-10-15 |
2022-05-26 |
Celgene Corporation |
Combination therapy for treating malignancies
|
EP3362065B1
(en)
|
2015-10-15 |
2024-04-03 |
Les Laboratoires Servier |
Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
AU2018252546A1
(en)
|
2017-04-13 |
2019-10-10 |
Sairopa B.V. |
Anti-SIRPα antibodies
|
ES2919779T3
(es)
|
2017-06-20 |
2022-07-28 |
Imbria Pharmaceuticals Inc |
Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
|
WO2019094311A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN112105608B
(zh)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(zh)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
一种咪唑甲胺类衍生物的制备方法
|
MX2020010322A
(es)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
WO2020092395A1
(en)
|
2018-10-29 |
2020-05-07 |
Forma Therapeutics, Inc. |
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
|
EP3927427B1
(en)
|
2019-12-20 |
2024-02-07 |
Nimmune Biopharma, Inc. |
Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|